经导管主动脉瓣植入术后抗栓治疗综述
本综述汇总经导管主动脉瓣植入(TAVI)术后抗栓治疗数据。缺乏大型随机试验时,临床实践倾向参考其他人群证据。因维生素K拮抗剂(VKA)出血风险高,抗血小板治疗(APT)可考虑作为TAVI术后一线治疗,总体优选单联而非双联APT;特定高危情况考虑双联APT。
要点
- TAVI术后一线可考虑APT,总体优选单联而非双联。
- 近期ACS(6个月内)、复杂冠脉支架、大主动脉弓粥样斑块或既往非心源性卒中者考虑双联APT。
- 合并房颤或需长期口服抗凝者考虑VKA单药;近期ACS、广泛或近期冠脉支架或大主动脉弓粥样斑块者可加用APT。
核心结论
- TAVI术后抗栓策略缺乏大型随机试验,实践多借鉴其他人群证据。
- 因VKA相关大出血风险较高,APT可考虑作为TAVI术后一线治疗,总体优选单联APT。
研究设计与样本
- 本文为综述,汇总TAVI术后抗栓治疗现有数据。
主要发现
- 缺乏大型随机临床试验,临床实践倾向参考其他人群证据。
- VKA口服抗凝与大出血风险较高相关。
- 总体优选单联APT而非双联APT。
- 近期ACS(6个月内)、复杂冠脉支架、大主动脉弓粥样斑块或既往非心源性卒中者应考虑双联APT。
- 合并房颤或其他需长期口服抗凝指征者考虑VKA单药;近期ACS、广泛或近期冠脉支架或大主动脉弓粥样斑块者可在VKA基础上加用APT。
关键数值与推荐
- 近期ACS定义为6个月内。
- 无口服抗凝指征且无禁忌时,可考虑直接口服抗凝药。
- 临床瓣膜血栓(如高跨瓣压差)推荐启动VKA;亚临床瓣叶血栓中VKA作用尚不确定。
临床怎么用
- TAVI术后默认优选单联APT;合并房颤等长期抗凝指征者考虑VKA单药。
- 近期ACS(6个月内)、复杂冠脉支架、大主动脉弓粥样斑块或既往非心源性卒中者考虑双联APT。
- 需口服抗凝且无禁忌时可考虑直接口服抗凝药;临床瓣膜血栓启动VKA。
局限性
- 缺乏大型随机临床试验,证据多来自其他人群。
- 亚临床瓣叶血栓中VKA的作用目前不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review provides a comprehensive overview of the available data on antithrombotic therapy after transcatheter aortic valve implantation (TAVI). In the absence of large randomised clinical trials, clinical practice is leaning towards evidence reported in other populations. Due to the greater risk of major bleeding associated with oral anticoagulation using a vitamin-K antagonist (VKA), antiplatelet therapy (APT) may be considered as the first-line treatment of patients undergoing TAVI. Overall, single rather than dual APT is preferred. However, dual APT should be considered in patients with a recent acute coronary syndrome (ie, within 6 months), complex coronary stenting, large aortic arch atheromas or previous non-cardioembolic stroke. Monotherapy with VKA should be considered if concomitant atrial fibrillation or any other indication for long-term oral anticoagulation is present. APT on top of VKA seems only reasonable in patients with recent acute coronary syndrome, extensive or recent coronary stenting or large aortic arch atheromas. A direct-acting oral anticoagulant may be considered if oral anticoagulation is indicated in the absence of contraindications. Initiation of VKA is indicated in clinical valve thrombosis, for example, with high transvalvular gradient, whereas the role of VKA in the case of subclinical leaflet thrombosis is currently uncertain.
引用
- Nijenhuis VJ, Brouwer J, Søndergaard L, et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019. PMID: 30867148. doi:10.1136/heartjnl-2018-314313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。